Dementia in Parkinson's disease is marked by cognitive deterioration in memory, executive function, and visuospatial abilities. Its presence indicates a faster disease progression and heightened mortality. Ongoing research is concentrated on pinpointing biomarkers for early Parkinson's dementia detection and creating targeted therapies to impede or delay cognitive decline.
In Huntington's disease, dementia involves cognitive regression in executive function, language, and behavior. Its presence correlates with a more pronounced motor phenotype and increased disability. Current research is directed towards comprehending the role of the huntingtin protein in cognitive decline and formulating neuroprotective therapies to decelerate the progression of Huntington's dementia.
The upcoming Alzheimer's 2024 conference is poised to be a significant milestone in neurodegenerative dementia research, offering fresh insights and optimism for enhanced diagnosis, treatment, and prevention of both Parkinson's and Huntington's dementia.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
